Literature DB >> 26382614

Ranking the harm of non-medically used prescription opioids in the UK.

Jan van Amsterdam1, Lawrence Phillips2, Graeme Henderson3, James Bell4, Owen Bowden-Jones5, Richard Hammersley6, John Ramsey7, Polly Taylor8, Annette Dale-Perera9, Jan Melichar10, Wim van den Brink11, David Nutt12.   

Abstract

A panel of nine experts applied multi-criteria decision analysis (MCDA) to determine the relative overall harm to users and harms to others of street heroin (injected and smoked) and eleven non-medically used prescription opioids. The experts assessed harm scores for each of the 13 opioids on each of 20 harm criteria, weighted the criteria and explored the resulting weighted harm scores for each opioid. Both forms of heroin scored very high: overall harm score of 99 for injected heroin and 72 for smoked heroin on a scale of 0-100. The main feature that distinguishes both forms of street heroin use is that their harm to others is more than five times that of the other eleven opioids. The overall harm score of fentanyl (including injection of fentanyl extracted from patches) and diamorphine (medically prescribed form of heroin) was 54 and 51, respectively, whereas that of orally used opioids ranged from 32 (pethidine) to 11 (codeine-containing pharmaceuticals). Injected street heroin, fentanyl and diamorphine emerged as most harmful to users, with the latter two very low in harm to others. Pethidine, methadone, morphine and oxycodone are also low in harm to others, while moderate in harm to users. We conclude that the overall harms of non-medically used prescription opioids are less than half that of injected street heroin. These data may give a basis for precautionary regulatory measures that should be considered if the rising trend in non-medical use of prescription opioids were to become evident in the UK.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Harm; MCDA; Opioids; Prescription drugs; Ranking; Risk assessment; Street heroin

Mesh:

Substances:

Year:  2015        PMID: 26382614     DOI: 10.1016/j.yrtph.2015.09.014

Source DB:  PubMed          Journal:  Regul Toxicol Pharmacol        ISSN: 0273-2300            Impact factor:   3.271


  7 in total

1.  Non-medical use of prescription opioids is associated with heroin initiation among US veterans: a prospective cohort study.

Authors:  Geetanjoli Banerjee; E Jennifer Edelman; Declan T Barry; William C Becker; Magdalena Cerdá; Stephen Crystal; Julie R Gaither; Adam J Gordon; Kirsha S Gordon; Robert D Kerns; Silvia S Martins; David A Fiellin; Brandon D L Marshall
Journal:  Addiction       Date:  2016-08-23       Impact factor: 6.526

2.  Medical professionals' perspectives on prescribed and over-the-counter medicines containing codeine: a cross-sectional study.

Authors:  Michelle Foley; Tara Carney; Eileen Rich; Charles Parry; Marie-Claire Van Hout; Paolo Deluca
Journal:  BMJ Open       Date:  2016-07-14       Impact factor: 2.692

3.  Toward an Improved Multi-Criteria Drug Harm Assessment Process and Evidence-Based Drug Policies.

Authors:  Veljko Dubljević
Journal:  Front Pharmacol       Date:  2018-08-20       Impact factor: 5.810

4.  Stratified analyses of genome wide association study data reveal haplotypes for a candidate gene on chromosome 2 (KIAA1211L) is associated with opioid use in patients of Arabian descent.

Authors:  Hiba Alblooshi; Habiba Al Safar; Ahmed El Kashef; Hamad Al Ghaferi; Mansour Shawky; Gary K Hulse; Guan K Tay
Journal:  BMC Psychiatry       Date:  2020-01-31       Impact factor: 3.630

5.  Ranking the Harm of Psychoactive Drugs Including Prescription Analgesics to Users and Others-A Perspective of German Addiction Medicine Experts.

Authors:  Udo Bonnet; Michael Specka; Michael Soyka; Thomas Alberti; Stefan Bender; Torsten Grigoleit; Leopold Hermle; Jörg Hilger; Thomas Hillemacher; Thomas Kuhlmann; Jens Kuhn; Christian Luckhaus; Christel Lüdecke; Jens Reimer; Udo Schneider; Welf Schroeder; Markus Stuppe; Gerhard A Wiesbeck; Norbert Wodarz; Heath McAnally; Norbert Scherbaum
Journal:  Front Psychiatry       Date:  2020-10-26       Impact factor: 4.157

6.  Developing a new national MDMA policy: Results of a multi-decision multi-criterion decision analysis.

Authors:  Jan van Amsterdam; Gjalt-Jorn Ygram Peters; Ed Pennings; Tom Blickman; Kaj Hollemans; Joost J Jacobus Breeksema; Johannes G Ramaekers; Cees Maris; Floor van Bakkum; Ton Nabben; Willem Scholten; Tjibbe Reitsma; Judith Noijen; Raoul Koning; Wim van den Brink
Journal:  J Psychopharmacol       Date:  2021-02-02       Impact factor: 4.153

7.  Effect of sustained high buprenorphine plasma concentrations on fentanyl-induced respiratory depression: A placebo-controlled crossover study in healthy volunteers and opioid-tolerant patients.

Authors:  Laurence M Moss; Marijke Hyke Algera; Robert Dobbins; Frank Gray; Stephanie Strafford; Amy Heath; Monique van Velzen; Jules A A C Heuberger; Marieke Niesters; Erik Olofsen; Celine M Laffont; Albert Dahan; Geert Jan Groeneveld
Journal:  PLoS One       Date:  2022-01-27       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.